The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sivolap Iu.P.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Antidepressants: the goals and possibilities of therapy

Authors:

Sivolap Iu.P.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12): 120‑124

DOI: 10.17116/jnevro2018118121120

Read: 6949 times

Download PDF (RU)
Contact the author
Table of contents

ANTIDEPRESSANTS: THE GOALS AND POSSIBILITIES OF THERAPY
ANTIDEPRESSANTS: THE GOALS AND POSSIBILITIES OF THERAPY

To cite this article:

Sivolap IuP. Antidepressants: the goals and possibilities of therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12):120‑124. (In Russ.)
https://doi.org/10.17116/jnevro2018118121120

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A personalized approach to the treatment of chro­nic tension headache and como­rbid mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):51-57
Asthenia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):5-10
The state of mental health of migrant workers and citi­zens of the Russian Fede­ration: A comparative analysis as illu­strated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101
Factors of depression acco­rding to acti­graphy in the fall season. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):27-32
Sleep diso­rders in imprinting diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):75-80
The effect of sleep and other medi­cal and social factors on a woman’s reproductive function. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):81-86
Identification of depression biomarkers: Prospects for use in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):51-55
Expe­rience with the use of amitriptyline for chro­nic pelvic pain asso­ciated with endo­metriosis. Russian Journal of Human Reproduction. 2025;(1):86-93
Prediction and prevention of burnout syndrome in health care professionals in high epidemic risk settings. Russian Journal of Preventive Medi­cine. 2025;(4):51-56
Asso­ciation of sleep diso­rders with APOE gene poly­morphisms among the resi­dents aged 25—64 years of the Novo­sibirsk city: WHO «MONICA psychosocial study». Russian Journal of Preventive Medi­cine. 2025;(5):75-81
Abstract:

Antidepressants are among the most commonly prescribed drugs due to their effectivenes in treating depression and anxiety disorders. One of the reasons for early discontinuation of taking antidepressants are side-effects. Agomelatine is a relatively novel antidepressant with high efficacy and good tolerance. Clinical effects of agomelatine include a reduction in symptoms of depression, anti-anxiety and hypnotic effects, as well as the rapid elimination of anhedonia, which determines high adherence to therapy, restoration of normal social functioning, and complete remission of disease.

Keywords:

depression
major depressive disorder
anhedonia
anxiety
sleep disorders
anxiety disorders
antidepressants
selective serotonin reuptake inhibitors
selective serotonin and norepinephrine reuptake inhibitors
agomelatine

Authors:

Sivolap Iu.P.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Close metadata

References:

  1. Pratt LA, Brody DJ, Gu Q. Antidepressant use among persons aged 12 and over: United States, 2011—2014. NCHS Data Brief. 2017;283:1-8.
  2. Schatzberg A, DeBattista C. Manual of Clinical Psychopharmacology (Eight Edition). Washington, DC: American Psychiatric Publishing; 2015.
  3. Krylov VI. Angedoniya pri rasstroystvakh affektivnogo i shizofrenicheskogo spektra: psikhopatologicheskiye osobennosti. diagnosticheskoye i prognosticheskoye znacheniye. Psikhiatriya i Psikhofarmakoterapiya. 2014;1:28-33. (In Russ.)
  4. Pinkerton JV, Stovall DW, Kightlinger RS. Advances in the treatment of menopausal symptoms. Womens-Health (Lond). 2009;5(4):361-384; quiz 383-384. https://doi.org/10.2217/whe.09.31
  5. Hill DA, Crider M, Hill SR. Hormone therapy and other treatments for symptoms of menopause. Am Fam Physician. 2016;94(11):884-889.
  6. Parissis J, Fountoulaki K, Paraskevaidis I, Kremastinos DT. Sertraline for the treatment of depression in coronary artery disease and heart failure. Expert Opin Pharmacother. 2007;8(10):1529-1537. https://doi.org/10.1517/14656566.8.10.1529
  7. Vadnie CA, McClung CA. Circadian rhythm disturbances in mood disorders: insights into the role of the suprachiasmatic nucleus. Neural Plast. 2017;1504507. https://doi.org/10.1155/2017/1504507
  8. Khoo AL, Zhou HJ, Teng M, Lin L, Zhao YJ, Soh LB, Mok YM, Lim BP, Gwee KP. Network meta-analysis and cost-effectiveness analysis of new generation antidepressants. CNS Drugs. 2015;29(8):695-712. https://doi.org/10.1007/s40263-015-0267-6
  9. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7
  10. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007;68(11):1723-1732.
  11. Pandi-Perumal SR, Srinivasan V, Cardinali DP, Monti MJ. Could agomelatine be the ideal antidepressant? Expert Rev Neurother. 2006;6(11):1595-1608. https://doi.org/10.1586/14737175.6.11.1595
  12. Martinotti G, Sepede G, Gambi F, Di Iorio G, De Berardis D, Di Nicola M, Onofrj M, Janiri L, Di Giannantonio M. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol. 2012;32(4):487-491. https://doi.org/10.1097/JCP.0b013e31825d6c25
  13. Signorelli MS, Concerto C, Battaglia E, Costanzo MC, Battaglia F, Aguglia E. Venlafaxine augmentation with agomelatine in a patient with obsessive-compulsive disorder and suicidal behaviors. SAGE Open Med Case Rep. 2014;2:2050313X14561778. https://doi.org/10.1177/2050313X14561778
  14. Buoli M, Grassi S, Serati M, Altamura AC. Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2017;18(13):1373-1379. https://doi.org/10.1080/14656566.2017.1359257
  15. Buoli M, Mauri MC, Altamura AC. Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder. Expert Opin Drug Metab Toxicol. 2014;10(6):885-892. https://doi.org/10.1517/17425255.2014.907794
  16. Semple D, Smyth R. Oxford Handbook of Psychiatry (Third Edition). Oxford: Oxford University Press; 2013.
  17. Lejoyeux M, Matharan S, de Bodinat C. How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine. CNS Spectr. 2015;20(1):29-38. https://doi.org/10.1017/S1092852913000813
  18. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004;19(5):271-280.
  19. Che T, Teng X, Huang Q, Mu Y, Tang X, Mu X, Wei Y. Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial. Neuropsychiatr Dis Treat. 2018;14:1527-1533. https://doi.org/10.2147/NDT.S167608
  20. Kang R, He Y, Yan Y, Li Z, Wu Y, Guo X, Liang Z, Jiang J. Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial. Neuropsychiatr Dis Treat. 2015;11:1307-1311. https://doi.org/10.2147/NDT.S85711
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.